Weakness and Fatigue in Cancer: What Causes Them and How Are They Treated?
In this article
Weakness and fatigue in cancer
The most misunderstood feature of cancer fatigue is that rest does not relieve it. Ordinary tiredness improves with sleep; cancer-related fatigue does not, and more rest deepens it. This article shows which treatments the best available evidence supports. The short answer may surprise readers: the most effective remedy for fatigue is not a drug.
- Exercise and psychological approaches are approximately three times more effective than drugs. A meta-analysis of 113 studies and 11.525 patients found effect sizes of: exercise 0,30, psychological treatments 0,27, and medications only 0,09 (p=0,05, borderline).
- No medication is approved for cancer fatigue. Methylphenidate, modafinil, L-carnitine and antidepressants have all produced negative or borderline results.
- Fatigue goes untreated because it is not discussed. In a meta-analysis, %23,6 reported severe fatigue, while physician assessment identified only %1,6 .
- Striking data from Türkiye: in a study of 100 chemotherapy patients, %86 had fatigue and approximately %73 chose reducing activity and resting more as their coping strategy—exactly the wrong approach.
- An important correction in anemia treatment: blood-production-stimulating medications (ESAs) must not be used in patients receiving curative treatment —they increase clot risk by %50-75 and data suggest adverse survival effects.
Weakness or fatigue? They are not the same
Weakness: Reduced muscle strength. Moving an arm or leg requires extra effort. The medical term is weakness. It occurs with muscle loss, nerve problems and electrolyte disturbances.
Fatigue: Feeling low in energy and needing rest. The medical term is fatigue. Strength may be preserved, but motivation and endurance are absent.
Sleepiness: The desire to sleep. It differs from fatigue: a fatigued person may be unable to sleep, while a sleepy person may not feel fatigued. This distinction directly changes treatment.
The core international definition is: "A distressing, persistent, subjective sense of physical, emotional and/or mental tiredness or exhaustion related to cancer or cancer treatment; disproportionate to recent activity and interfering with daily functioning."
The distinguishing feature: ordinary tiredness resolves with rest; cancer-related fatigue does not. Waking equally exhausted after a full night goes beyond saying “I am tired”; it has a medical name, diagnostic criteria and even a disease code (R53.0).
How common is it, and why is it not discussed?
A meta-analysis of 57 studies and 34.310 patients found:
The same analysis’s most striking finding: %23,6 of patients self-reported severe fatigue, versus %1,6 on physician assessment. The difference exceeds fifteenfold.
Rather than physician inattention, this is a communication gap: patients normalize fatigue as part of cancer and do not mention it; if not asked, it goes unrecorded. An unrecorded symptom is untreated.
A Turkish study shows the other half of this gap: among 100 chemotherapy patients, %86 had fatigue and approximately %73 chose “reducing activity and resting more” to cope. As shown below, this opposes evidence-based advice and creates a vicious circle: less movement → deconditioning → more fatigue → less movement.
Measuring it: One question scored 0-10
Measurement is uncomplicated. Guidelines recommend, as with pain, a score from 0-10: "Over the last week, what was your average fatigue? 0 means none, 10 the worst imaginable."
| Score | Meaning | What to do? |
|---|---|---|
| 0-3 | None or mild | Information, energy management, regular exercise; reassess during follow-up |
| 4-6 | Moderate | The clinically meaningful threshold is 4. Investigate treatable causes and begin exercise and behavioral approaches |
| 7-10 | Severe | Detailed assessment: review anemia, thyroid, sleep disturbance, depression, pain and medications individually |
Guidelines recommend asking at the first visit, before and during treatment, and at least annually afterward . Patients can also ask themselves and bring their score to appointments—the simplest practical step toward closing the %23,6 versus %1,6 gap.
First look for treatable causes
Cancer fatigue has multiple mechanisms: cancer- and treatment-related inflammation, effects on brain alertness and dopamine systems, hormonal-axis changes and immune responses. Before surrendering to this complexity, exclude correctable causes one by one.
| Cause to investigate | What to do? |
|---|---|
| Anemia | Complete blood count, iron stores, B12 and folate. See the box below—treatment selection is critical. |
| Underactive thyroid | Check TSH. Some immunotherapies and neck irradiation affect the thyroid; it is easily detected and treated. |
| Low testosterone | Particularly in men receiving hormone suppression for prostate cancer , it is an important fatigue component. |
| Depression and anxiety | Often overlap with fatigue but are not the same (below). Assess and treat them separately. |
| Sleep disorders | Especially insomnia. This cause has the highest-effect treatment in the fatigue field—see below. |
| Pain | Uncontrolled pain drains both sleep and energy. |
| Medications | Opioids, antihistamines, some blood pressure drugs (beta blockers), sleeping pills and anti-nausea drugs contribute to fatigue. Medication review is the cheapest and often overlooked intervention. |
| Electrolyte and organ disorders | Sodium, potassium, calcium; kidney, liver and heart function. |
| Deconditioning | Prolonged inactivity reduces muscle mass and endurance. It is both a consequence and cause of fatigue; this is where the vicious circle can be broken. |
“Drugs increasing blood production may be an option” is incomplete and misleading. The joint ASCO/ASH guideline strongly states for erythropoiesis-stimulating agents (ESAs):
- "ESAs should not be offered for chemotherapy-associated anemia when cancer treatment is curative in intent." This is a strong recommendation.
- They may be considered only with noncurative-intent chemotherapy and hemoglobin below 10 g/dL.
- They increase clot risk by %50-75.
- Data show reduced survival, increased mortality and progression/recurrence risk, and no subgroup proven safe has been identified.
- There is no optimal defined hemoglobin target; use the lowest dose avoiding transfusion.
Iron is different: the same guideline permits iron with ESAs and states intravenous iron is superior to oral iron . Correcting iron deficiency in anemia is defensible.
In contrast: No validated randomized evidence shows vitamin D, B12 or iron supplements treat fatigue in cancer without anemia. Correct deficiencies if present, but do not market supplements as fatigue treatments.
What works? The field’s most important table
A meta-analysis of 113 studies and 11.525 patients directly compared approaches. Its findings reverse the order in most patient information:
Subgroups also guide care: exercise effects were greater during treatment (0,34) than afterward (0,26); psychological effects were greatest after treatment ended (0,42). Among psychological methods, cognitive behavioral therapy (0,37) substantially outperformed information alone (0,17).
First line: movement
Telling an exhausted person to move may sound cruel. But rest is not a treatment for cancer fatigue; it is part of a cycle feeding fatigue through deconditioning. Türkiye’s %73 “I rested more” finding shows how widespread this is.
The practical guideline target during and after treatment is 150 minutes of moderate aerobic activity weekly plus strength work two days weekly; a simple fatigue prescription is moderate walking 3 days weekly, 30 minutes each. Guidelines state that exercise during active treatment has “a low risk of adverse effects” .
- Start where you are. If 30 minutes is too much, start with 5. Aim for slightly more than you can do today, not somebody else’s standard.
- Consistency matters more than intensity. Gentle walking three times weekly is much more effective than strenuous exercise once monthly.
- Do not skip strength work. Some fatigue directly reflects muscle loss, not restored by walking alone. Light weights, resistance bands or body-weight movements suffice.
- Use your best time of day. Energy fluctuates; schedule exercise at its peak.
- Consult your physician first in certain circumstances: bone metastases, low blood counts (especially platelets and hemoglobin), fever or active infection, new chest pain or breathlessness, balance problems and fall risk. Exercise is generally something to adapt, not prohibit —swimming or a stationary bicycle may suit bone metastases better than high-impact running. Note: exact numerical thresholds could not be verified, so none are provided; your treatment team decides.
Second line: sleep and mind
In a meta-analysis of 61 randomized studies and 6.528 patients, the effect size of CBT for insomnia was 0,86 (%95 CI 0,57-1,15). Although falling to 0,55 at follow-up, this is the largest effect measured in the field and also improves fatigue.
Compare exercise’s fatigue effect of 0,30 and medication’s 0,09. If insomnia accompanies fatigue, this therapy, not a sleeping pill, is the first destination. It is nonpharmacological, learnable and lasting.
Cognitive behavioral therapy directly targeting fatigue also works (0,37), particularly after treatment ends (0,42 for psychological approaches). Information alone has a much smaller effect (0,17); saying “fatigue is normal” is not treatment.
Mindfulness-based methods are recommended during and after treatment in guidelines. Energy management —scheduling important tasks during higher energy, dividing work and asking for help—is sensible but weakly supported alone; it complements rather than replaces exercise.
Medications: the honest picture
For cancer fatigue, not one medication is approved , not because none were tried but because trials failed. The following table is the article’s most extensively corrected section.
| Drug | Evidence | Judgment |
|---|---|---|
| Methylphenidate (stimulant) |
A meta-analysis of 9 randomized studies and 668 patients found an effect size of 0,23 (%95 CI 0,06-0,40). The authors’ words: “insufficient to support widespread clinical practice.” | Insufficient for routine use. A leading journal editorial title sums it up: “Time to put methylphenidate for cancer fatigue on the shelf?” |
| Modafinil (wakefulness-promoting) |
In a study of 631 patients, benefit appeared only in those with severe baseline fatigue ; none in mild or moderate fatigue. | Not supported for general use. Discussable in severe cases. |
| L-carnitine | 376 patients in phase III, daily 2×1 g for 4 weeks: fatigue-score reduction −0,96 (drug) vs −1,11 (placebo), p=0,57. | Clearly negative. Listed as “not recommended” in guidelines. |
| Antidepressants (paroxetine) | In 94 patients, depression scores significantly improved (p=0,006), but all fatigue measures had p>0,27 —none significant. | An instructive result: depression improved, fatigue did not. Fatigue is not depression , and depression treatment does not replace fatigue treatment. Treat depression when present, but make a separate fatigue plan. |
| Corticosteroids (dexamethasone) | 84 advanced cancer patients, daily 2×4 mg, 14 days: significant fatigue-score improvement on day 15 (p=0,001). | A real but narrow role: only in advanced disease with limited life expectancy, short use for 1-2 weeks. Long-term benefit is unproven; use over weeks causes serious muscle loss, infection, high glucose and sleep disturbances, potentially increasing fatigue. This indication does not apply to most readers. |
| Megestrol, donepezil, armodafinil | No confirmed positive phase III result | No routine role |
Complementary methods
| Method | Evidence and guideline status |
|---|---|
| American ginseng (Panax quinquefolius) |
In a study analyzing 341 patients, daily 2.000 mg Wisconsin ginseng, 8 weeks: no significant difference at week 4 (14,4 vs 8,2; p=0,07), significant at week 8 (20 vs 10,3; p=0,003); benefit was prominent in patients receiving treatment . No additional toxicity occurred. Current guidelines include it among recommended options during treatment. Two critical details: (1) Species matters—American ginseng (P. quinquefolius) differs from Asian ginseng (P. ginseng); (2) the study used a non-alcohol-extracted preparation. Not every shelf product labeled “ginseng” is the studied preparation. |
| Acupuncture | A 302-patient study reported significant fatigue improvement (p<0,001). Important limitation: There was no sham (placebo) acupuncture arm or blinding, so effects of the method cannot be separated from attention and expectations. Meta-analyses show benefit particularly in breast cancer. |
| Yoga, tai chi and qigong | Combine gentle activity with mental relaxation. Guidelines recommend tai chi and qigong during treatment, and yoga after treatment . |
| Not recommended | Current guidelines for cancer fatigue do not recommend L-carnitine, antidepressants, wakefulness agents or stimulants. Evidence for guarana and coenzyme Q10 is also insufficient. |
| Herbal mixtures and high-dose supplements | Neither therapeutic effects nor interactions with cancer drugs are known. Effects of high doses in humans remain uncertain. Do not risk current treatment with products of unknown consequences —tell your oncologist about every supplement. |
Frequently asked questions
- Does fatigue mean my cancer is progressing?
- Usually not. It may reflect treatment, anemia, sleep problems, pain, medications or deconditioning, independent of disease course. Nevertheless, new or rapidly worsening fatigue must be reported because correctable causes need assessment.
- I am tired—will rest not help?
- This is precisely what distinguishes cancer-related fatigue: it does not resolve with rest. Reducing activity also decreases muscle and endurance, worsening fatigue. In a Turkish study, about %73 chose this very strategy. Balance rest with movement and do not abandon activity completely.
- Is fatigue depression?
- No, but they often coexist. The clearest evidence is a paroxetine study: depression scores improved significantly (p=0,006), but no fatigue measure improved (p>0,27). Treating depression therefore does not treat fatigue. Assess and address them separately.
- Are there no fatigue medications?
- None is approved. Methylphenidate, modafinil, L-carnitine and antidepressants all had negative or borderline results; average drug effects were 0,09 (borderline), versus exercise’s 0,30. The one real exception: in advanced cancer with limited life expectancy, corticosteroids for 1-2 weeks genuinely work, but are not a long-term solution.
- Can I use ginseng?
- Species and preparation matter. The positive study used American ginseng (Panax quinquefolius), daily 2.000 mg in a non-alcohol-extracted preparation, with benefit at week 8. Asian ginseng is a different plant. Always report supplements to your oncologist.
- I cannot sleep—can I request a sleeping pill?
- Discuss another option first. For insomnia, cognitive behavioral therapy in a meta-analysis of 61 studies and 6.528 patients achieved an effect size of 0,86—the field’s highest measured effect—and also improves fatigue. It is nonpharmacological and persists after therapy ends. Sleeping pills can increase daytime fatigue, so do not reverse this order.
Glossary
- Cancer-related fatigue (CRF)
- Persistent exhaustion related to cancer or treatment, disproportionate to recent activity and unrelieved by rest . It has a separate disease code (R53.0).
- Weakness
- Reduced muscle strength, distinct from fatigue.
- Effect size
- A number allowing treatment effectiveness to be compared across scales. Approximately 0,20 is small, 0,50 moderate and 0,80 large.
- Meta-analysis
- Statistically combining results of multiple studies investigating the same question.
- Cognitive behavioral therapy (CBT)
- A structured, time-limited psychotherapy targeting thought and behavior patterns. Its insomnia-adapted form (CBT-I; Turkish abbreviation BDT-U) is the field’s most effective treatment.
- ESA (erythropoiesis-stimulating agent)
- Medications stimulating blood production in bone marrow, subject to strict restrictions in cancer.
- Deconditioning
- Inactivity-related loss of muscle mass and endurance, both a consequence and cause of fatigue.
- Placebo-controlled / blinding
- A study design in which patients, and preferably assessors, do not know the treatment received. Without this, treatment effects cannot be separated from other improvements.
DROZDOGAN Academy Commentary
Fatigue is oncology’s most common but least discussed symptom. Preparing this article, we were struck that the most effective treatment is not a drug, despite most patient information presenting the opposite order.
⚡ Why does this matter?
More than half our patients have fatigue, one-quarter severely. Yet physician records capture %1,6. This is not a diagnosis problem but a raising-the-issue problem. Fatigue affects walking, work, social life, willingness to continue treatment and morale simultaneously—and none are addressed when it is not discussed.
✅ Strengths / improvements
We have a clear answer, not always true in oncology. The 11.525-patient meta-analysis directly demonstrated exercise and psychological approaches outperforming drugs. CBT for insomnia’s 0,86 effect is among supportive care’s largest. Guidelines now recommend asking at the first visit and measuring throughout follow-up. Safety data have clarified limits of once freely prescribed anemia drugs.
⚠️ Limitations / what not to exaggerate
Exercise’s effect size of 0,30 is small to moderate —it reduces fatigue rather than eliminating it. Exaggeration disappoints patients. The largest acupuncture trial lacked sham acupuncture, leaving the method-specific contribution unclear. Ginseng findings concern one species and preparation, not any shelf product. Corticosteroid benefit is real but was shown in 84 patients over 14 days , not grounds for months of cortisone. We found no verified thresholds defining exercise limits with bone metastases or low blood counts.
🩺 Our practical position
- We ask and score at the first visit. “Over the past week, what was your fatigue from 0-10?” This question closes the %23,6 versus %1,6 gap.
- At scores of 4 or above, we exclude correctable causes individually: anemia, thyroid, testosterone, sleep, pain, depression and the medication list. Medication review is the cheapest, most frequently overlooked intervention.
- We prescribe exercise rather than merely recommending it —duration, frequency and type in writing. “Move” is not a plan.
- For insomnia, we discuss behavioral therapy first, not sleeping pills. Effect-size differences require this order.
- We treat depression without attributing all fatigue to it. The paroxetine study shows why this distinction matters.
- For blood-production-stimulating drugs, we follow guidelines: not used with curative-intent treatment. For iron deficiency, intravenous iron is preferred.
- We start corticosteroids only in advanced disease, specifying duration from the outset : one–two weeks, then review.
❓ Open questions
Inflammatory and neuroendocrine mechanisms are known, but no targeted drug exists; thirty years of stimulant trials have failed. Clear exercise thresholds with bone metastases or low counts remain absent. National Turkish prevalence is unknown; our only concrete data are a single-center study of 100 patients more than a decade ago.
- Corrections: “Blood-production-stimulating drugs may be an option” was corrected by adding the strong guideline recommendation against use with curative treatment, the %50-75 clot-risk increase and survival signals. Ginseng was rewritten with original study numbers and species/preparation cautions; the old statement “no physical performance improvement” could not be verified—the available meta-analysis showed the opposite pattern: significant physical well-being effects and borderline fatigue effects. Corticosteroid advice now includes patient count, duration (14 days) and limited life expectancy. Drugs were moved last with meta-analysis effect sizes. Lack of blinding was added to acupuncture limitations.
- Additions: Measurement scales and thresholds; patient–physician reporting differences; L-carnitine, paroxetine, methylphenidate and modafinil results; CBT for insomnia; Turkish data.
- No numbers given because not verified: Direct aerobic-versus-strength exercise comparison; exercise guideline evidence grades; exact exercise thresholds with bone metastases and low counts; detailed mean values from modafinil and dexamethasone studies; pooled acupuncture effect size; fatigue-specific bright-light effects; numerical guarana and coenzyme Q10 data.
- Guideline access: Anemia and ESA recommendations were verified from full text. Current complementary-method recommendations come from secondary sources, and recommendation-specific evidence grades could not be verified; therefore, no grades are given.
- Türkiye: No national or multicenter prevalence data were found; the cited data concern a single-center study of 100 patients in Ankara. No SGK reimbursement information is provided.
- Internal links (“Related topics”) partly retain existing links and are partly estimated; they should be checked before publication.
This article is informational, not individualized medical advice. Consult your treatment team before exercise or supplements.
References
- Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3(7):961-968.
- Prevalence and severity of cancer-related fatigue: a systematic review and meta-analysis. Sci Rep. 2023.
- Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197-1210.
- Bower JE, Lacchetti C, Alici Y, et al. Management of fatigue in adult survivors of cancer: ASCO-Society for Integrative Oncology guideline update. J Clin Oncol. 2024;42(20):2456-2487.
- Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol. 2014;32(17):1840-1850.
- Barton DL, Liu H, Dakhil SR, et al. Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230-1238.
- Cruciani RA, et al. L-carnitine supplementation for the management of fatigue in patients with cancer: an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol.
- Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076-3082.
- Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat.
- Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue. Cancer. 2010;116(14):3513-3520.
- Molassiotis A, Bardy J, Finnegan-John J, et al. Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial. J Clin Oncol. 2012;30(36):4470-4476.
- Cognitive behavioral therapy for insomnia in cancer patients: a systematic review and meta-analysis. JNCI Cancer Spectr. 2024;8(3):pkae041.
- Can G, Durna Z, Aydiner A. Assessment of fatigue in and care needs of Turkish women with breast cancer. Oncol Nurs Forum. 2007;34(3):664.
- National Cancer Institute. Fatigue (PDQ) — Health Professional Version.
- Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 2022.
Sources
Moderate-intensity exercise reduces fatigue and improves mobility in cancer survivors: a systematic review and meta-regression.
J Physiother. 2016 Apr;62(2):68-82
2. Yennurajalingam S, Bruera E.
Role of corticosteroids for fatigue in advanced incurable cancer: is it a 'wonder drug' or 'deal with the devil'.
Curr Opin Support Palliat Care. 2014 Dec;8(4):346-51.
3. Elisabeth C.W. Neefjes ve ark.
Aiming for a Better Understanding andManagement of Cancer-Related Fatigue.
TheOncologist2013;18:1135–1143
4. Hoang Viet Bach, Jeongseon Kim, Seung-Kwon Myung, and Young Ae Cho.
Efficacy of Ginseng Supplements on Fatigue and Physical Performance: a Meta-analysis.
J Korean Med Sci. 2016 Dec;31(12):1879-1886
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.